Nicole Macagno

ORCID: 0000-0002-0097-2139
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Psoriasis: Treatment and Pathogenesis
  • Dermatology and Skin Diseases
  • Cutaneous lymphoproliferative disorders research
  • Lymphoma Diagnosis and Treatment
  • Cutaneous Melanoma Detection and Management
  • Asthma and respiratory diseases
  • Nail Diseases and Treatments
  • Autoimmune Bullous Skin Diseases
  • Nonmelanoma Skin Cancer Studies
  • Cancer Treatment and Pharmacology
  • CAR-T cell therapy research
  • Urticaria and Related Conditions
  • Cancer and Skin Lesions
  • Chronic Lymphocytic Leukemia Research
  • Immunotherapy and Immune Responses
  • Cancer Immunotherapy and Biomarkers
  • Skin Protection and Aging
  • Advancements in Transdermal Drug Delivery
  • Drug-Induced Ocular Toxicity
  • Mast cells and histamine
  • Genetic and rare skin diseases.
  • Microscopic Colitis
  • Acne and Rosacea Treatments and Effects
  • Multiple Myeloma Research and Treatments
  • Syphilis Diagnosis and Treatment

University of Turin
2022-2025

Metropolitan University
2022

Introduction Psoriasis affecting the genital, palmoplantar, and scalp regions is recognized as difficult-to-treat, data on efficacy of biologics in these areas remains limited.Research design methods This single-center study evaluated effectiveness anti-IL-17 anti-IL-23 agents scalp, palmoplantar psoriasis. We retrospectively analyzed from all patients with psoriasis being treated IL inhibitors at our clinic. Effectiveness was 16, 28, 52 weeks, according to achievement relative mean PSSI,...

10.1080/14712598.2023.2236023 article EN Expert Opinion on Biological Therapy 2023-07-17

Patients with treated solid tumors (TST) are a highly heterogeneous and difficult-to-treat population due to the risk of disease progression/recurrence or infection.

10.3390/jcm13216546 article EN Journal of Clinical Medicine 2024-10-31

Introduction: There are few long-term effectiveness and safety data for dupilumab in the treatment of atopic dermatitis (AD). The aim this study was to evaluate efficacy up three years after initiation. Materials Methods: We collected from patients ≥ 12 with severe AD who started at Dermatology Clinic Turin University Hospital between December 2018 October 2022. patient reported outcomes were evaluated baseline, 3 (T9), every 4 months. Results: A total 418 observed. progressive decrease...

10.3390/cosmetics10060153 article EN cc-by Cosmetics 2023-11-07

Inverse psoriasis (IP) is a variant of plaque involving flexor surfaces. A clear definition IP still lacking. Therapy based on topical and systemic treatments, including classic drugs biologic agents, but well-defined therapeutic strategy absent.

10.1111/ijd.17252 article EN International Journal of Dermatology 2024-05-15

De-escalation strategies have become increasingly used in the treatment of atopic Dermatitis® (AD) patients with dupilumab. Dose spacing (DS) refers to dose reduction by dosage elongation from 2 8 weeks between dupilumab injections, stable response or affected numerous adverse events.

10.1089/derm.2024.0146 article EN Dermatitis 2024-07-22

Background: Advancements in managing stage III melanoma have involved the implementation of adjuvant therapies alongside a simultaneous decrease utilization completion lymph node dissection (CLND) following positive sentinel biopsy (SLNB). Methods: This retrospective study from University Turin’s Dermatology Clinic analyzed relapse-free survival (RFS) and overall (OS) among patients (n = 157) who underwent CLND after SLNB versus those did not receive such procedure. Results: Patients without...

10.3390/jcm13175238 article EN Journal of Clinical Medicine 2024-09-04

Primary cutaneous lymphomas (PCL) are rare diseases, but the indolent course makes their prevalence high. Although there many treatment options, no hierarchy is recommended.To identify burden of PCL and describe clinical-pathologic features; associated comorbidities; analyse approaches in real-life parameters with achievement complete response (CR).In this study, all patients (384 patients) consecutively seen at Dermatologic Clinic University Turin from January 1, 2019 to December 31, 2019,...

10.1111/jdv.18469 article EN Journal of the European Academy of Dermatology and Venereology 2022-07-26

Introduction . Psoriasis of the scalp, genital areas, and palms soles represents a treatment challenge in clinical practice. Randomized trials real‐life studies investigating efficacy biological drugs these sites are scarce. The present is descriptive retrospective study with aim to evaluate safety brodalumab difficult‐to‐treat areas. Materials Methods 158 psoriatic patients scalp involvement, 69 54 palmoplantar involvement being treated were assessed at weeks 16, 28, 48 using PSSI...

10.1155/2023/1793535 article EN cc-by Dermatologic Therapy 2023-01-01

Abstract Background Solid organ transplant recipients (SOTRs) have an increased risk of developing non melanoma skin cancers (NMSCs). The use Imiquimod, a toll‐like‐receptor agonist, is still debated in SOTRs. Objectives aim this study was to evaluate efficacy and safety topical Imiquimod two Dermatology Centres for Methods All SOTRs with age > 18 dermoscopic diagnosis superficial basal cell carcinoma (BCC) and/or actinic keratose (AK), annually followed up between January 2022 December...

10.1002/jvc2.376 article EN cc-by-nc JEADV Clinical Practice 2024-06-25

Mycosis fungoides (MF) is the most common cutaneous T-cell lymphoma (CTCL) that typically presents in early phase as inflammatory erythematous patches or plaques, with epidermotropism histopathological hallmark of disease. Traditionally, stages, non-aggressive options represent first-line strategy: topical corticosteroids, phototherapy, radiotherapy, and occasionally adopting a "wait-and-see" approach for minimally symptomatic patients. In patients advanced recurrent disease, good results...

10.4081/dr.2024.10002 article EN cc-by-nc Dermatology Reports 2024-10-02

Psoriasis (PSO) involves about 1-3% of the population, and around 75% women develop PSO before age 40. Official guidelines on treatment woman with anti-IL17 anti-IL23 during this potential childbearing time are not currently available.

10.3390/jcm13216401 article EN Journal of Clinical Medicine 2024-10-25
Coming Soon ...